Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (GREY:FRTX)

Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020

GlobeNewswire May 4, 2020

Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 18, 2020

Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020

GlobeNewswire March 9, 2020

Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide

GlobeNewswire March 4, 2020

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

GlobeNewswire February 20, 2020

Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

GlobeNewswire February 18, 2020

Brickell Bio's Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

GlobeNewswire January 10, 2020

Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2019

Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

GlobeNewswire October 30, 2019

Brickell Biotech Completes Merger with Vical

GlobeNewswire September 3, 2019

Mid-Afternoon Market Update: Tile Shop Drops On Weak Sales Forecast; Endocyte Shares Spike Higher

Benzinga.com  October 3, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  October 3, 2017

Mid-Morning Market Update: Markets Open Higher; Paychex Profit Beats Estimates

Benzinga.com  October 3, 2017

Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial

GlobeNewswire October 2, 2017

Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences

GlobeNewswire September 28, 2017

Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire September 6, 2017

Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017

Accesswire August 8, 2017

Investor Network: Vical Incorporated to Host Earnings Call

Accesswire August 8, 2017

Vical Reports Second Quarter 2017 Financial and Operational Results

GlobeNewswire August 8, 2017

Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results

GlobeNewswire August 1, 2017